Cannabinoid Therapeutic Solutions

In June 2026, we celebrated an important milestone in Linnea's journey: the inauguration of our new production building.

Sustainability is a company-wide priority:we partner with local farmers in the Swiss canton of Ticino converting organic waste into energy thanks to a biogas plant, and we voluntarily adhere to the Swiss Private Sector Energy Agency Program, for a minimal CO2 footprint.

In February 2026 Linnea's Cannabidiol Isolate has successfully obtained the CEP certification (Certificate of Suitability to the European Pharmacopoeia).

LINNEA’S GINKGO BILOBA BOTANICAL EXTRACT IS AN EFFECTIVE ACTIVE INGREDIENT THAT EMBODIES THE COMPANY PHILOSOPHY AND COMMITMENT TO QUALITY WHILE BENEFITING BOTH BODY AND MIND.

The European Directorate for the Quality of Medicines & Healthcare (EDQM) has issued a CEP certificate for our Vincamine product, making Linnea the first company in the world to have a CEP-certified Vincamine extract.

BY CLOSELY MONITORING THE ENTIRE PRODUCTION CHAIN, LINNEAENSURES UNIFORMITY AND RELIABILITY ACROSS ALL BATCHES OF ITS REDCLOVER EXTRACT, COMPOSED OF A PRECISE RATIO OF FOUR DIFFERENT ISOFLAVONES (FORMONONETIN, BIOCHAIN A, GENISTEIN AND DAIDZEIN).

Linnea is proud to comply with the new CBD monograph issued by the European Pharmacopoeia. This monograph is applicable for medical prescriptions, pharmacy compounding, clinical trials, pharmaceutical development, and registrations.

OUR HMRLIGNAN™ IS A CONCENTRATED WELLSPRING OF HEALTH, PROVIDING EXPONENTIALLY MORE LIGNANS COMPARED TO DIETARY SOURCES.

Linnea SA (“Linnea” or “the Company”), is proud to announce that it is celebrating the Company’s 40th anniversary in 2022. Linnea has been manufacturing high quality botanical ingredients at their GMP certified facility in Ticino, Switzerland since 1982

A snapshot of Linnea, its mission, vision, commitment to the environment and product sheets of the full Linnea API portfolio.

At LINNEA we use innovative technology to transform natural botanical raw materials into high quality trusted ingredients that will improve people’s lives.

An overview on the company strengths and products' assets

A thorough insight on Linnea's GMP, pharma-grade cannabinoids (CBD, CBG, THC)

A peripherally-acting antimuscarinic and anticholinergic agent, Linnea hasproduced Butylscopolamine since 1982. This semi-synthetic derivative isobtained from the leaves of the Duboisia plant in Linnea’s plantation in Australia.

Here you can find Linnea Cannabinoids brochure. You can also visit our Cannabinoids webiste at: www.linneacannabinoids.ch